Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | CRHBP | P24387 | 1/20 | 0.67 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30040198 | 0.88 | LMNA (0.79) | LMNAGAAHTTNPC1PDE4D | |
| SCHEMBL7821807 | 0.88 | LMNA (0.79) | LMNAGAAHTTNPC1PDE4D | |
| SCHEMBL6201848 | 0.83 | S1PR5 (0.58) | TSHRKMT2AS1PR5 | |
| SCHEMBL3943149 | 0.81 | LMNA (0.83) | LMNAGAAHTTNPC1PDE4D | |
| SCHEMBL10956366 | 0.79 | NPC1 (0.62) | LMNAHTTNPC1PDE4DMAPT | |
| SCHEMBL1515747 | 0.79 | NPC1 (0.63) | LMNAGAAHTTNPC1PDE4D | |
| SCHEMBL5210966 | 0.78 | LMNA (0.52) | LMNAGAACRHBPCRHR2HTT | |
| SCHEMBL29689390 | 0.78 | LMNA (0.68) | LMNAGAAHTTNPC1MAPT | |
| SCHEMBL30969381 | 0.78 | LMNA (0.64) | LMNAGAAHTTNPC1PDE4D | |
| SCHEMBL29236768 | 0.78 | LMNA (0.68) | LMNAGAAHTTNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347967-B1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-7192950-B2 | Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-03-20 | — | — | US | disclosed |
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-03-25 | — | — | US | disclosed |
| EP-1347967-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002051838-A1 | NOVEL BENZAZEPINES AND RELATED HETEROCYCLIC DERIVATIVES WHICH ARE USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058912-A1 | Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | LMNA 2249/4885GAA 1588/4885CRHBP 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.